CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Which treatment first? landmark trial may guide melanoma care
Disease control OngoingThis phase III trial tested two different sequences of treatments for people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib),…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
Immunotherapy timing may boost melanoma survival
Disease control OngoingThis study compares giving the immunotherapy drug pembrolizumab both before and after surgery versus only after surgery for people with stage III-IV high-risk melanoma. The goal is to see if the combined approach improves event-free survival. About 313 participants are enrolled, …
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of sonidegib combined with pembrolizumab in 36 adults with advanced solid tumors (cancers that have spread). Sonidegib blocks enzymes that help tumors grow, while pembrolizumab boosts the immune system to attack cancer. The go…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New combo aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New hope for melanoma patients: could pembrolizumab outperform current treatments?
Disease control OngoingThis study compared pembrolizumab (Keytruda) to the usual treatments (high-dose interferon or ipilimumab) in over 1,300 people with high-risk melanoma that was surgically removed. The goal was to see if pembrolizumab could better prevent the cancer from coming back or spreading. …
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for hard-to-treat melanoma: drug combo targets resistant tumors
Disease control OngoingThis study tests whether adding rigosertib to pembrolizumab can help people with advanced melanoma that did not respond to previous immunotherapy. Rigosertib may block cancer cell growth and make the immune system more responsive to pembrolizumab. The trial enrolled 7 adults with…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC
-
New combo therapy aims to shrink melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with melanoma that can be surgically removed. About 60 adults with stage III melanoma will receive treatment before surgery to see if…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC
-
Triple drug cocktail takes on tough melanoma
Disease control OngoingThis study tests a combination of three drugs—dabrafenib, trametinib, and navitoclax—in people with BRAF mutant melanoma or other solid tumors that have spread or can't be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 adu…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 01, 2026 18:04 UTC
-
Facebook groups tested to boost skin checks in young melanoma families
Knowledge-focused OngoingThis study looks at whether a private Facebook group can help young adults (ages 18-39) diagnosed with early-stage melanoma and their close family members do more skin checks and use better sun protection. About 1,160 participants will join either a melanoma-focused Facebook grou…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:09 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC
-
Melanoma survivors: how does immunotherapy affect your daily life?
Knowledge-focused OngoingThis study looks at side effects and overall well-being in people who have had melanoma and are now getting immunotherapy to prevent the cancer from coming back. Researchers will track side effects and ask participants about their quality of life, depression, and fatigue for up t…
Matched conditions: CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:08 UTC